Clinical Trial Update: Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment for Triple Negative Breast Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating autologous hematopoietic stem cell transplantation as adjuvant treatment for patients with residual tumor after triple-negativ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Autologous hematopoietic stem cell transplantation (Autologous hematopoietic stem cell transplantation)

Snippet

Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | Conditions: Triple-Negative Invasive Breast Carcinoma, Residual Tumor | Phase 2 | Status: UNKNOWN